Sold as Mesnex. Every FDA application for this active ingredient: 2 branded and 9 generic.
As of Nov 13, 2026, FDA lists 11 applications for Mesna (sold as Mesnex), first approved Dec 30, 1988, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Mesnex | Part D | $690K | -2% | 302 |
| Mesna | Part B | $11K | -23% | 99 |
| Mesna | Part D | $5K | -13% | 13 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 30, 1988 | MesnexNDA 19884 · New molecular entity | Baxter Hlthcare | 10 | Marketed |
| Apr 26, 2001 | MesnaANDA 75811 | Fresenius Kabi USA | 4 | Marketed |
| Apr 27, 2001 | MesnaANDA 75764 | Teva Pharms USA | 4 | Discontinued |
| Mar 21, 2002 | MesnexNDA 20855 · New dosage form | Baxter Hlthcare | 3 | Marketed |
| Jan 9, 2004 | MesnaANDA 75739 | Hikma | 3 | Marketed |
| Apr 13, 2010 | MesnaANDA 90913 | Sagent Pharms Inc | 2 | Marketed |
| Mar 8, 2012 | MesnaANDA 76488 | Mylan Institutional | 1 | Discontinued |
| Jul 18, 2014 | MesnaANDA 203364 | Rising | 1 | Discontinued |
| Dec 18, 2017 | MesnaANDA 206992 | Gland | 2 | Marketed |
| Jan 13, 2025 | MesnaANDA 218871 | Ingenus Pharms LLC | 0 | Marketed |
| Jan 27, 2026 | MesnaANDA 220518 | Eugia Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
